These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2287059)

  • 1. [Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium].
    Daimon Y
    Jpn J Antibiot; 1990 Nov; 43(11):1948-55. PubMed ID: 2287059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Susceptibilities of clinical bacterial isolates to antimicrobial agents. A study mainly focused on imipenem. Reported by the Research Group for Testing Imipenem Susceptibility on Clinical Isolates].
    Igari J
    Jpn J Antibiot; 1990 Nov; 43(11):1956-2002. PubMed ID: 2287060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical laboratory approach to estimating the effective administration dose of imipenem/cilastatin. Evaluation of the disk susceptibility test and its interpretation system].
    Matsuo K; Uete T
    Jpn J Antibiot; 1989 Nov; 42(11):2377-92. PubMed ID: 2621780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro antibacterial activity of a new parenteral penem, sulopenem].
    Yoshida T; Tateda E; Hiramatsu K; Yokota T
    Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Susceptibilities of clinical bacterial isolates to antimicrobial agents. A study mainly focused on imipenem. Research Group for Testing Imipenem Susceptibility on Clinical Isolates].
    Igari J
    Jpn J Antibiot; 1990 Oct; 43(10):1723-82. PubMed ID: 2086814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Susceptibilities of clinical bacterial isolates to antimicrobial agents, 1989. A study mainly focused on imipenem. The Research Group for Testing Imipenem Susceptibilities of Clinical Isolates].
    Igari J
    Jpn J Antibiot; 1991 Dec; 44(12):1329-40. PubMed ID: 1798067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1992). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Nov; 48(11):1627-57. PubMed ID: 8558754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2003 Oct; 56(5):458-96. PubMed ID: 14692381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria].
    Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T
    Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Susceptibility of clinically isolated strains to aztreonam].
    Daimon Y
    Jpn J Antibiot; 1988 Nov; 41(11):1623-34. PubMed ID: 3145344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Susceptibilities of clinical isolates to antibacterial agents. A study mainly focused on ofloxacin (the second report). Reported by the Research Group for Testing ofloxacin Susceptibility on Clinical Isolates].
    Kosakai N
    Jpn J Antibiot; 1989 May; 42(5):1125-65. PubMed ID: 2664255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro and in vivo antibacterial activities of sulopenem, a new penem antibiotic].
    Komoto A; Otsuki M; Nishino T
    Jpn J Antibiot; 1996 Apr; 49(4):352-66. PubMed ID: 8786626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
    Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic, bacteriological and clinical studies on imipenem/cilastatin sodium in neonates].
    Hashira S; Tajima T; Fujii R
    Jpn J Antibiot; 1989 May; 42(5):1077-86. PubMed ID: 2746857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antibacterial activities of monobactams against fresh clinical isolates].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukayama S; Nishimura Y; Oda S; Tanaka S; Kato M; Sato K
    Jpn J Antibiot; 1988 Nov; 41(11):1600-22. PubMed ID: 3210297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Susceptibility of clinical isolates to aztreonam].
    Nagasawa Z; Nishimura T; Nagumo F; Ueda H; Tadano J; Katoh O; Yamada H
    Jpn J Antibiot; 1989 Jun; 42(6):1257-70. PubMed ID: 2507799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.